Search results
Key Points. This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
18 paź 2009 · This paper reviews the evidence supporting the safety and efficacy of available methods of contraception for cancer survivors and concludes that the Copper T380A intrauterine device (IUD), a highly effective, reversible, long-acting, hormone-free method should be considered a first-line contraceptive option for women with a history of a hormonal...
14 maj 2021 · Prospective trials 63 and large retrospective cohorts 64,65 confirm the potential large benefit of adjuvant chemotherapy on breast cancer-specific survival or overall survival mostly in oestrogen receptor-negative disease, irrespective of nodal status.
23 wrz 2022 · This analysis of the CANTO cohort study used prospectively collected data at different time points to provide distinct insights on contraceptive use and factors associated with contraceptive use over time among premenopausal women with early breast cancer. Overall, 54.2% of patients reported contraceptive use at the time of breast cancer ...
1 mar 2021 · Because many breast cancers are ER/PR positive, there is concern that exogenous hormones could increase the risk of recurrence by stimulating remaining breast tissue or clinically occult circulating metastatic ER/PR expressing breast cancer cells.
4 lip 2024 · Mirena is a type of intrauterine devices (IUD) that prevents pregnancy for up to 6 years. It works by releasing a hormone called levonorgestrel, a type of progestin. Because of this, Mirena is...
Introduction: Epidemiological studies have shown that some hormonal contraceptive methods are associated with increased breast cancer risk, especially if used over long periods.
